

VolitionRx

10:08 05 Dec 2019

VolitionRx and partner win \$1M grant to develop lung cancer blood test

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Thursday that it and Gyros Protein Technologies AB have been awarded more than \$1 million to collaborate on developing a lung cancer blood test.

VolitionRx will receive \$820,000 (€740,000) and Gyros Protein Technologies, now part of Mesa Laboratories Inc (NASDAQ:MLAB), will get \$230,000 (€206,000) in the form of a non-repayable Eurostars cash grant, according to a statement.

The grant proceeds are to be used towards the development of novel, high sensitivity assays and a validated panel ready for regulatory trials through the combination of VolitionRx's propriety Nu.QTM platform and Gyros Protein Technologies' Gyrolab technology.

READ: VolitionRx unveils promising proof-of-concept data for leukemia and lymphoma tests

The resulting blood-based test will be used for triaging individuals testing positive in Low Dose CT lung cancer screening.

"This Eurostars funding will greatly assist with the development of our groundbreaking Nu.QTM technology on a new high sensitivity platform, in addition to our current ELISA plate and bead-based assays," Marielle Herzog, research and development director with Belgian Volition SPRL, the company's Belgium-based subsidiary.

"We are very excited to yet again broaden the range of our technology platform by working with Gyros Protein Technologies, who we believe has excellent immunoassay solutions that should complement the work we are doing."

VolitionRx and Gyros Protein Technologies will collaborate to develop 12 novel Research Use Only liquid biopsy assays based on VolitionRx's Nu.QTM immunoassays and Gyros Protein Technologies' Gyrolab platform to profile unique circulating cell-free nucleosomes.

Combining both technologies, the assays will be supported by a new ultra-sensitive Gyrolab Bioaffy CD and Nu.QTM profiles to differentiate lung cancer from benign disease.

Headquartered in Isnes, Belgium, VolitionRx said a validated triage panel will be developed in a prospectively collected cohort, with the goal to be ready for regulatory trials.


"Lung cancer is the leading cause of cancer death worldwide and has the lowest five-year survival rate of any cancer, with less than half of cases detected at early, treatable stages," said Ivan Kamensky, divisional vice president of operations and research and development at Gyros Protein Technologies.

"We believe Volition's innovative biomarker panels have the potential to greatly improve the standard of care for those

Price: 4.57

Market Cap: \$188.31 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	6.83	2.65

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. .

action@proactiveinvestors.com

at high risk of lung cancer, and we are grateful to Eurostars for funding this collaborative project."

Eurostars is a European joint program, co-funded from the national budgets of 36 EUREKA countries and by the European Union through Horizon 2020.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).